For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126

Notice regarding The Open Offer for Shares in Ranbaxy Laboratories Limited

Tokyo, September 24, 2008  --  Daiichi Sankyo Company, Limited (TSE: Daiichi Sankyo/4568, Head Office in Tokyo, Japan) ("Daiichi Sankyo") has made the open offer for common shares in Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359; Head Office in Delhi, India) ("Ranbaxy"), which had been conducted during the period from August 16, 2008 to September 4, 2008  (the “Offer”).

In response to the Offer, the number of shares tendered by the shareholders exceeded the offer size of 92,519,126 fully paid-up equity shares of Ranbaxy, representing 20% of the Emerging Voting Capital. As per the schedule of activities, the last date for making payment for the validly tendered and accepted shares and return of unaccepted shares was September 19, 2008. The Offer is subject to the receipt of certain statutory/regulatory approvals by Daiichi Sankyo. However, as on the date of this announcement, certain approvals for the Offer are yet to be received.

As required under Securities and Exchange Board of India (“SEBI”) Regulations, Daiichi Sankyo has agreed to pay interest to the shareholders of Ranbaxy for delay in payment of consideration beyond 15 days from the closure of the Offer. Also, in consultation with SEBI, the equity shares which are in excess, following determination of the proposed allocation, will be released/dispatched (where shares are in physical form) to the relevant beneficiaries. However, it may be noted that the return of the unaccepted shares shall not be deemed acceptance of the shares retained by the Acquirer. The acceptance of the shares retained is contingent on statutory approvals being received.

<Disclaimer>

Statements contained in this press release regarding the benefits of the acquisition, the business outlook, the demand for the products and services, and all other statements in this release other than recitation of historical facts are forward-looking statements. Words such as “expect”, “estimate”, “project”, “budget”, “forecast”, “anticipate”, “intend”, “plan”, “may”, “will”, “could”, “should”, “believes”, “predicts”, “potential”, “continue”, and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, forecasts of market growth, future revenues, benefits of the proposed acquisition, expectations that the acquisition will be accretive to the results, future expectations concerning growth of business, cost competitiveness and expansion of global reach following the acquisition, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: difficulties encountered in integrating businesses; uncertainties as to the timing of the acquisition; approval of the preferential allotment/transaction by the shareholders of Ranbaxy; the satisfaction of the closing conditions to the transaction, including the receipt of regulatory approvals; whether certain market segments grow as anticipated; the competitive environment in the pharmaceutical industry and competitive responses to the proposed acquisition; and whether the companies can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release.

This document does not constitute an offer to purchase or to sell securities in any jurisdiction.